MVIR:STO
Medivir AB
SEK 1.49
arrow_downward
-1.33%(-0.020) 1D
Okt 13, 11:57:24 AM GMT+2 · SEK
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa MVIR...
Buksan
SEK 1.50
Mataas
SEK 1.51
Mababa
SEK 1.48
Mkt. cap
930.02M
Avg. na dami
1.46M
Dami
366.52K
Mataas nang 52-wk
SEK 2.88
Mababa nang 52-wk
SEK 0.34
EPS
-SEK 0.37
Mga natitirang share
624.18M
Bilang ng mga empleyado
6
Buksan
SEK 1.50
Mataas
SEK 1.51
Mababa
SEK 1.48
Mkt. cap
930.02M
Avg. na dami
1.46M
Dami
366.52K
Mataas nang 52-wk
SEK 2.88
Mababa nang 52-wk
SEK 0.34
EPS
-SEK 0.37
Mga natitirang share
624.18M
Bilang ng mga empleyado
6
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Investing.com
·
52 minuto ang nakalipas
S&P futures erase declines with bank earnings slate ahead
The Guardian
·
6 araw ang nakalipas
S&P 500 and Nasdaq surge to record highs after AI chipmaker rally
Benzinga
·
5 araw ang nakalipas
Michael Burry Warns Anthropic’s Valuation Could Buy 78 Profitable S&P 500 Companies: ‘Fun Game in Times L
Bloomberg.com
·
1 linggo ang nakalipas
S&P 500 Closes In on Record High as Tech Rallies: Markets Wrap
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Tungkol sa Medivir AB